The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

SHELTON, CT / ACCESS Newswire / January 27, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has ...

Brii said it agreed to purchase the assets from VBI Vaccines Inc. and its creditors for $18 million. The deal gives Brii full access to the remaining IP, patents and materials related to BRII-179, an ...

Breakthrough therapy designation recognises the potential of brelovitug to transform the lives of people living with CHD. We ...

The initial diagnosis of chronic HBV infection can be made by the use of serological markers. The presence of HBsAg generally indicates chronic infection, while antibodies directed against HBsAg ...

Hepatitis B is inflammation of the liver in hominoidea, including humans, caused by the hepatitis B virus. The virus is transmitted by parenteral exposure, such as by exposure to infectious blood ...

The phase 3 program missed both primary and key secondary endpoints, with no statistically significant effects on relevant measures observed for patients receiving investigational treatment ...

The cease-fire deal reached Wednesday between Israel and Hamas is the first step in a process that could see the release of all hostages from the Gaza Strip and the withdrawal of the Israeli military.

You can contract hepatitis C by blood-to-blood contact. Ways to avoid reinfection to the hepatitis C virus include avoiding sharing needles and using condoms or another barrier method during sex.

What our study showed was that during a chronic hepatitis C infection, antibodies on the virus surface form an antibody cluster that persistently stimulates the B cells to mutate," explains lead ...

according to the final results of the Phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. "KATHERINE is a landmark clinical ...